Beta Bionics Secures $204M to Accelerate the Future of Automated Diabetes Care

Beta Bionics is thrilled to announce the successful completion of a $204,000,000 funding round—a significant milestone that underscores the industry’s confidence in the company’s innovative approach to diabetes care. As a commercial-stage medical technology company, Beta Bionics is dedicated to transforming the lives of insulin-requiring people with diabetes through its groundbreaking iLet Bionic Pancreas, the first FDA-cleared autonomous insulin delivery device on the market. This revolutionary system utilizes advanced adaptive algorithms designed to simplify diabetes management, offering patients improved overall outcomes and a better quality of life. The newly secured funding will be strategically invested in further refining the iLet Bionic Pancreas’s technology, expanding research and development capabilities, and accelerating the commercialization process to reach broader populations of patients worldwide. In addition, Beta Bionics plans to bolster regulatory efforts and operational infrastructure, ensuring that its products not only meet but exceed the highest standards of safety and efficacy. This investment also positions the company to explore additional innovative solutions and partnerships that will address unmet needs in diabetes care, reaffirming its commitment to enhancing the health and well-being of patients across a diverse spectrum of communities. As Beta Bionics continues to lead the charge in the medical technology space, this funding round is a testament to the company’s vision and the transformative potential of its products. For more information about Beta Bionics, its groundbreaking iLet Bionic Pancreas, and details on safety information, please visit www.betabionics.com and www.betabionics.com/safety.